ImmunityBio (IBRX) Net Cash Flow (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Net Cash Flow data on file, last reported at $116.9 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $116.9 million, up 241.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $145.1 million (up 300.94% YoY), and the FY2025 annual result was -$54.5 million, up 55.28% from the prior year.
• Net Cash Flow grew to $116.9 million in Q1 2026 per IBRX's latest filing, from $28.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $134.5 million in Q3 2023 and troughed at -$144.5 million in Q1 2022.
• A 5-year average of $1.5 million and a median of $319000.0 in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow plunged 1564.0% in 2022, then surged 27334.8% in 2023.
• A 5-year view of Net Cash Flow shows it stood at $319000.0 in 2022, then surged by 27334.8% to $87.5 million in 2023, then slumped by 63.87% to $31.6 million in 2024, then retreated by 11.16% to $28.1 million in 2025, then soared by 316.09% to $116.9 million in 2026.
• Business Quant data shows IBRX's Net Cash Flow at $116.9 million in Q1 2026, $28.1 million in Q4 2025, and -$76.7 million in Q3 2025.